TendieTensor TendieTensor
You’re browsing as
Guest
Free Preview
Sign in/sign up to unlock all features.

News  ›  GlobeNewswire Inc.

MediciNova Announces Update and Basic Characteristic Randomized Patients’ of Phase 2/3 Clinical Trial of MN-166 (Ibudilast) in ALS (COMBAT-ALS Clinical Trial) Presented at the 36th International Symposium on ALS/MND

GlobeNewswire Inc. Logo GlobeNewswire Inc. By Medicinova, Inc.
MediciNova Announces Update and Basic Characteristic Randomized Patients’ of Phase 2/3 Clinical Trial of MN-166 (Ibudilast) in ALS (COMBAT-ALS Clinical Trial) Presented at the 36th International Symposium on ALS/MND

MediciNova completed randomization of 234 patients in its COMBAT-ALS clinical trial for MN-166, a potential treatment for Amyotrophic Lateral Sclerosis. The company anticipates top-line data by end of 2026 and remains hopeful about the drug's therapeutic potential.

Insights
TSM   positive

World's leading chip manufacturer with strong demand in AI computing power and manufacturing capabilities


MNOV   positive

Company successfully completed patient randomization, received regulatory designations, and remains optimistic about potential treatment breakthrough for ALS